Myocarditis Following Immune Checkpoint Inhibition With Pembrolizumab: Management in a Context of Steroid Intolerance

Immune checkpoint inhibitors (ICIs) are a major advance in oncology and have become first- or second-line therapy for over 50% of oncology patients. ICI-associated myocarditis is a complication that, although rare, has a high mortality rate. We present a case of ICI-associated myocarditis presenting...

Descripción completa

Detalles Bibliográficos
Autores principales: Onderko, Laura L., Heinrich, Ross, Gosling, Katalin, Downs, Tim, Afari, Maxwell Eyram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568688/
https://www.ncbi.nlm.nih.gov/pubmed/36254327
http://dx.doi.org/10.1016/j.cjco.2022.07.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568688/
https://www.ncbi.nlm.nih.gov/pubmed/36254327
http://dx.doi.org/10.1016/j.cjco.2022.07.002

Ejemplares similares